A Phase 3 Randomized, Observer-Blind, Multi-center, Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects ≥18 Years of Age
Phase of Trial: Phase III
Latest Information Update: 25 Oct 2017
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary)
- Indications Influenza A virus H5N1 subtype
- Focus Pharmacodynamics
- Sponsors Seqirus
- 17 Oct 2017 Status changed from active, no longer recruiting to completed.
- 26 Oct 2016 Planned End Date changed from 1 Oct 2017 to 1 Nov 2017.
- 26 Oct 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Nov 2017.